Karyopharm Therapeutics Inc.
KPTI
$5.40
$0.459.09%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 30.54M | 38.78M | 42.79M | 33.13M | 33.75M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.54M | 38.78M | 42.79M | 33.13M | 33.75M |
| Cost of Revenue | -108.60M | 37.43M | 39.84M | 37.34M | -97.88M |
| Gross Profit | 139.14M | 1.35M | 2.95M | -4.21M | 131.63M |
| SG&A Expenses | 27.19M | 27.63M | 31.07M | 29.55M | 30.69M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 61.82M | 65.07M | 70.91M | 66.89M | 71.56M |
| Operating Income | -31.28M | -26.28M | -28.12M | -33.76M | -37.81M |
| Income Before Tax | -30.89M | -32.04M | 23.86M | -37.29M | -41.71M |
| Income Tax Expenses | -109.00K | 28.00K | 67.00K | 71.00K | 130.00K |
| Earnings from Continuing Operations | -30.78M | -32.07M | 23.79M | -37.36M | -41.84M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.78M | -32.07M | 23.79M | -37.36M | -41.84M |
| EBIT | -31.28M | -26.28M | -28.12M | -33.76M | -37.81M |
| EBITDA | -31.20M | -26.20M | -28.03M | -33.67M | -37.73M |
| EPS Basic | -3.67 | -3.85 | 2.26 | -4.13 | -5.47 |
| Normalized Basic EPS | -2.30 | -2.40 | -1.61 | -3.03 | -3.41 |
| EPS Diluted | -3.70 | -3.90 | -2.97 | -4.13 | -5.47 |
| Normalized Diluted EPS | -2.30 | -2.40 | -1.27 | -3.03 | -3.41 |
| Average Basic Shares Outstanding | 8.39M | 8.33M | 8.07M | 7.70M | 7.65M |
| Average Diluted Shares Outstanding | 8.39M | 8.33M | 10.30M | 7.70M | 7.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |